Prevencio

Prevencio is a private, commercial-stage diagnostics company leveraging artificial intelligence and multi-analyte biomarker panels to revolutionize cardiovascular disease testing. Its core HART tests are designed to address significant unmet needs in emergency medicine and cardiology by improving diagnostic accuracy over traditional single-biomarker tests and imaging, potentially reducing unnecessary procedures and costs. The company has seven tests on the market, supported by publications and key opinion leader endorsements, and is targeting the massive global cardiovascular disease market. Its business model is focused on commercializing these proprietary blood tests to healthcare providers and patients.

AI-powered, multi-protein biomarker analysis platform using machine learning algorithms to integrate multiplexed protein data with clinical variables for cardiovascular disease diagnosis and risk prediction.

Prevencio competes with established single-biomarker blood tests (e.g., troponin, BNP), non-invasive imaging (stress tests, CT angiography, coronary calcium scoring), and clinical risk scores (e.g., Framingham). It also faces potential competition from other emerging multi-marker assays and large diagnostic companies (e.g., Roche, Abbott, Siemens) that could develop similar AI-enhanced panels. Its differentiation hinges on the demonstrated superior accuracy of its proprietary multi-protein, AI-algorithmic approach.